RESEARCH
Gut bacteria engineered to convert cholesterol into a tumor-suppressing metabolite show promise in preclinical colorectal cancer models — Nature: Colorectal Cancer
Researchers identified a cholesterol metabolite called 4-cholesten-3-one (4-C-3) that is depleted in colorectal cancer and can suppress tumor growth by blocking EGFR (epidermal growth factor receptor) activation and stabilizing mutant KRAS in an inactive state. In preclinical models, restoring 4-C-3 using either a naturally occurring gut bacterium or an engineered non-pathogenic Escherichia coli lowered intratumoral cholesterol and induced tumor regression without overt toxicity. The approach overcame KRAS-driven resistance to anti-EGFR therapy in laboratory models.
What this means
This preclinical work suggests a novel route to target colorectal cancer through the gut microbiome, particularly for tumors carrying KRAS mutations that typically resist standard therapies. Whether microbiome engineering can be translated safely and effectively into clinical practice remains an open question.